Last reviewed · How we verify
NCT04932317
Oral Symptom Assessment Scale (OSAS): Validity and Reliability
trial in Neoplasms in 54 participants. Completed in 30 August 2022.
30 August 2022
Quick facts
| Lead sponsor | Our Lady's Hospice and Care Services |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 54 |
| Start date | 5 August 2021 |
| Primary completion | 30 August 2022 |
| Estimated completion | 30 August 2022 |
| Sites | 1 location across Ireland |
Conditions studied
- Neoplasms — all drugs for Neoplasms →
Sponsor
Our Lady's Hospice and Care Services
Who can join
18 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Oral (mouth) symptoms are very common and often bothersome in patients with cancer. The best way to assess these symptoms is using a patient-rated symptom assessment scale. A new symptom assessment scale for oral symptoms has been developed and already tested in patients. The purpose of this study is to test the scale again to make sure it is reliable and accurate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04932317
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoplasms
Currently open trials in the same condition.
- NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
- NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
- NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting
Other Our Lady's Hospice and Care Services trials
Trials by the same sponsor.
- NCT07512505 — Remote Vital Sign Monitoring in Palliative Care Patients Using a Wearable ECG Monitor · recruiting
- NCT07068971 — Sleep Well At Night · NA · enrolling by invitation
- NCT07411105 — Cognition in Older Adults With Cancer Receiving Systemic Anti-Cancer Therapy · active not recruiting
- NCT06587321 — Remote Assessment of Signs and Symptoms in Palliative Care · recruiting
- NCT06287294 — An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04932317 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Our Lady's Hospice and Care Services
- Last refreshed: 31 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04932317.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing